Site News
Military escalation between Saudi Arabia and the Houthis: missiles intercepted over Riyadh and strikes on al‑Hudaydah and Sana’aIs the post-antibiotic era approaching? WHO warns of bacteria that resist the strongest drugs and threaten millions of livesFirst publicly disclosed AI-powered cyberattack on the European Union: Has the world entered the era of automated hacking?Gold plunge shakes global markets as prices fall 34% from their record high and the US dollar reshapes market dynamicsBanque du Liban to cut interest paid to banks by 95% starting in 2027: What happens to banks’ and depositors’ money?Iraq avoids armed confrontation with Kataib Hezbollah as a politically backed security deal and Iranian intervention reshape control of Jurf al-SakharFadel Shaker sings about love in the Gulf dialect in “Omri al-Baqi”Shenzhen Summit: A Real Test of the Balance of Power
Economy

Eli Lillys Amylin Obesity Drug Shows Up To 20% Weight Loss In Study

100%
Eli Lillyon Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study.

The highest dose of the weekly injection, called eloralintide, helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks. The results support the pharmaceutical giant’s efforts to bring next-generation treatments to the blockbuster weight loss drug market, and solidify its dominance in the segment.

The data bolsters Eli Lilly’s chances of bringing a strong competitor to the red-hot amylin space, in particular. Many industry analysts view so-called amylin analogs as the next wave of obesity treatments that could serve as an alternative or complementary option to existing injections targeting gut hormone GLP-1.

Several large drugmakers such asRocheandAbbViehave shelled out billions to buy or license experimental amylin treatments, andNovo Nordiskis developing its own drugs. Novo Nordisk — Eli Lilly’s chief rival in the obesity market — andPfizerare also in the midst of a heated takeover war over Metsera, whose pipeline includes a potential once-monthly amylin drug.

Amylin analogs mimic a hormone co-secreted with insulin in the pancreas to suppress appetite and reduce food intake. Amylin treatments have a similar effect to GLP-1s like Lilly’s Zepbound and Mounjaro, but some analysts and researchers say it could be easier for patients to tolerate and help them preserve lean muscle mass.

The lowest dose of Eli Lilly’s injection helped people lose 9.5% of their weight at 48 weeks, compared to 0.4% among those who received a placebo. Patients who used a two-step dose escalation – starting at a 6 milligram dose and increasing to a 9 milligram dose – lost 19.9% of their weight at 48 weeks. People who used a three-step dose escalation that started at 3 milligrams lost 16.4% of their weight.

The most common side effects of the injection were mild to moderate gastrointestinal symptoms and fatigue, which were observed frequently in patients who took higher doses of the drug, according to Eli Lilly. Patients in groups that gradually increased doses of the drug saw lower side effects.

The company has yet to release detailed data on side effect rates and how many patients discontinued the treatment during the trial. Eli Lilly will present the data at the ObesityWeek scientific conference in Atlanta on Thursday.

Disclaimer: This news article has been republished exactly as it appeared on its original source, without any modification.
We do not take any responsibility for its content, which remains solely the responsibility of the original publisher.


Disclaimer: This news article has been republished exactly as it appeared on its original source, without any modification.
We do not take any responsibility for its content, which remains solely the responsibility of the original publisher.


Author: uaetodaynews
Published on: 2025-11-08 05:51:00
Source: uaetodaynews.com

aroundworldnews.com — News Update